LifeSci‑IP is an independent advisory led by Brad Salcedo, Esq., working with life science teams globally. We help founders treat IP as a core strategic asset; one that shapes valuation, strengthens partnerships, and reduces risk. As your fractional IP attorney, we support everything from patent strategy and invention capture to FTO, diligence, commercial agreements, and post‑deal integration. By combining scientific understanding with strategic execution, LifeSci‑IP connects the lab bench to the boardroom, turning breakthrough ideas into protection that endures.
We work as a fractional IP attorney and advisor, so you get senior-level judgment without the cost of building it in-house. The work spans patent portfolio strategy and governance, invention capture, freedom-to-operate, due diligence, commercial agreements and post-transaction integration — connected into decisions your leadership team can actually act on.
LifeSci-IP sits at the intersection of science, strategy and execution. We pair deep technical and regulatory understanding with commercial judgment, so your IP stays aligned to the pipeline, the market and the next milestone — not just the filing deadline.Think of us as the bridge between the lab bench and the boardroom — translating what you've invented into protection that holds up under diligence and value you can take to the table.
Brad Salcedo, Esq. brings more than 30 years guiding biologics, neuroscience, diagnostics and medtech programs for leaders including Ipsen, bioMérieux, Syngenta and Medtronic (Tyco/Covidien).
Get experienced IP leadership exactly when you need it — for a single filing decision, a diligence sprint or an ongoing advisory role — without adding a full-time hire.
We align IP work to R&D, regulatory and commercial milestones, so every decision moves you toward exclusivity, partnerships and valuation — not just a cleared action item.
Deep scientific grounding combined with a former examiner's view of how patents are actually read means fewer surprises and claims built to survive scrutiny.
We start with where you're headed — pipeline, funding plans, partnerships, exits — then map where IP can protect value and where it's quietly creating risk.
We shape a filing and portfolio strategy aligned to your products and priorities: what to protect, where, when, and what to let go.
FTO, invention capture, diligence and agreement review are handled with speed and precision, so launches and deals move forward on solid ground.
You get clear, executive-level read-outs on position, risk and options — the kind of input a board or investor can act on with confidence.
An IP attorney and strategist with more than 30 years guiding biologics, neuroscience, diagnostics and medtech programs — including work for Ipsen, bioMérieux, Syngenta and Medtronic. He turns intellectual property into a strategic asset for life science companies.
A former USPTO Primary Patent Examiner with a PhD and more than a decade examining biotechnology applications. Recognized with an Exceptional Career Achievement Award (2024) and a Bronze Medal for Excellence (2017), she brings the patent office's perspective to strategy.
Clarity over complexity guides everything we do: we tell you what a strategy will and won't do, in plain language, and tie every recommendation to a business reason. We keep IP aligned to the pipeline and the next milestone, and we measure the work by the decisions it enables — not the volume of filings.
Protecting innovation shouldn't mean drowning in legal process. LifeSci-IP is a practical partner for IP strategy, risk reduction and value creation — from the first invention to the final deal.
